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Parametric response mapping (PRM) is a novel computed tomography (CT) technology 
that has shown potential for assessment of bronchiolitis obliterans syndrome (BOS) 
after hematopoietic stem cell transplantation (HCT). The primary aim of this study 
was to evaluate whether variations in image acquisition under real-world conditions 
affect the PRM measurements of clinically diagnosed BOS. CT scans were obtained 
retrospectively from 72 HCT recipients with BOS and graft-versus-host disease from 
Fred Hutchinson Cancer Research Center, Karolinska Institute, and the University of 
Michigan. Whole lung volumetric scans were performed at inspiration and expira-
tion using site-specific acquisition and reconstruction protocols. PRM and pulmonary 
function measurements were assessed. Patients with moderately severe BOS at diag-
nosis (median forced expiratory volume at 1 second [FEV1] 53.5% predicted) had sim-
ilar characteristics between sites. Variations in site-specific CT acquisition protocols 
had a negligible effect on the PRM-derived small airways disease (SAD), that is, BOS 
measurements. PRM-derived SAD was found to correlate with FEV1% predicted and 
FEV1/ forced vital capacity (R = −0.236, P = .046; and R = −0.689, P < .0001, respec-
tively), which suggests that elevated levels in the PRM measurements are primarily 
affected by BOS airflow obstruction and not CT scan acquisition parameters. Based 
on these results, PRM may be applied broadly for post-HCT diagnosis and monitoring 
of BOS.
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1  | INTRODUC TION
Bronchiolitis obliterans syndrome (BOS) is a chronic obstructive 
airway disease associated with chronic graft-versus-host disease 
(GVHD) that occurs in 5%-12% of allogeneic hematopoietic cell 
transplant (allo-HCT) recipients.1-7 The disorder is characterized by 
progressive fibro-obliteration of terminal bronchioles, with resultant 
air trapping, progressive dyspnea, recurrent pulmonary infections, 
and an overall decrease in quality of life as well as increased nonre-
lapse mortality.8 Most patients do not come to clinical attention until 
symptoms arise, at which point lung function decline is already se-
vere and irreversible. The ability to identify and treat patients earlier 
in their clinical course is critical to reducing the morbidity and mortal-
ity associated with this condition.9 The National Institutes of Health 
(NIH) consensus guidelines for the diagnosis of chronic GVHD, how-
ever, do not allow for recognition of early BOS, atypical phenotypes 
of airflow obstruction, or restrictive lung disease (RLD).10 Novel im-
aging biomarkers that can serve as an adjunct to standard spirometry 
are needed to improve the assessment of early disease.
Parametric response mapping (PRM) is a voxel-based approach for 
analyzing high-resolution X-ray computed tomography (HRCT) images 
that provides detailed information on disease phenotype otherwise 
unattainable by conventional CT-based quantitative measures.11 Using 
inspiratory and expiratory HRCT scans, PRM allows for the quantifica-
tion of small airway disease (SAD) that contributes to airflow obstruc-
tion. PRM has been developed as a quantitative imaging biomarker for 
the assessment of obstructive lung disease in both chronic obstructive 
pulmonary disease (COPD) 11 and BOS postlung allografts.12,13 The 
potential utility of PRM for assessing SAD due to BOS after HCT has 
been recently examined in a single center cohort of BOS after allo-HCT 
with and without the presence of infection. Although a specific PRM 
signature was capable of identifying BOS even in the presence of inter-
stitial pneumonitis in HCT recipients from a single site,14 variability in 
CT acquisition may affect the ability to apply PRM CT scans acquired 
at multiple sites. The primary aim of the current study was to evaluate 
whether variations in image acquisition under real-world conditions af-
fect the PRM measurements of clinically diagnosed BOS. In addition, 
we describe features of PRM that may distinguish between pheno-
types of BOS and RLD potentially related to chronic GVHD.
2  | MATERIAL S AND METHODS
2.1 | Subjects
Allo-HCT recipients diagnosed with BOS were accrued as part of 
a multicenter retrospective observational study. Participating sites 
included the Karolinska University Hospital (KI), Fred Hutchinson 
Cancer Research Center (FH), and University of Michigan (UM). Any 
patients with a clinical diagnosis of BOS between the years 2000 
and 2015, with a high-resolution chest CT and a pulmonary func-
tion test within 28 days of BOS diagnosis, were included. Additional 
subjects with chronic GVHD and restrictive lung disease were also 
included for an exploratory analysis. The study was approved by the 
Institutional Review Boards (IRBs) at all participating sites. In addi-
tion, all patients had signed an IRB-approved informed consent for 
data collection and analysis.
Pulmonary function tests (PFTs) were obtained as per clinical 
care guidelines of each respective institution. Forced expiratory 
volume in 1 second percent predicted (FEV1%), forced vital capac-
ity percent predicted (FVC%), FEV1/FVC ratio, and total lung ca-
pacity percent predicted (TLC%) were based on accepted reference 
values that reflected the population served by each institution 
(Table 1). The clinical diagnosis of BOS was established on a site-
by-site basis through clinical care. These criteria included modified 
NIH consensus criteria: FEV1 < 75% predicted, signs of obstruc-
tive airway disease (FEV1/FVC ratio <0.7, residual volume [RV] 
> 120% predicted, or evidence of air trapping on high-resolution 
CT), the absence of infection, and the presence of chronic GVHD 
in another organ.15 Additional criteria for BOS diagnosis included 
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TA B L E  1   Subject characteristics at each site
 KI FH UM
Number of cases (N) 12 48 12
Age (y) 44.7 (15.9) 56.2 (15) 59.3 (12)
Sex (M/F) 7/5 29/19 8/4
Height (cm) 67 (12.8) 74.8 (20.8) 70.9 (16.9)
Weight (kg) 169.7 (8) 169.6 (10.9) 172.5 (5.6)
Diagnosed Post-Tx (y) 1.96 (2.32) 3.04 (2.17) 1.33 (0.71)†
FEV1 (% predicted) 49.5 (21.8) 54.0 (25.8) 61.0 (22.5)
FVC (% predicted) 65.5 (23.0) 81.5(23.5)* 76.0 (30.3)
FEV1/FVC 0.72 (0.29) 0.55 (0.25)* 0.55 (0.16; 
N = 10)P = .06
TLC (% predicted) 84.0 (31.3) 96.0 (20.0) 112.0 (33.0; 
N = 5)
Note: Data are presented as the mean (standard deviation), except for 
FEV1, FVC, FEV1/FVC, and TLC presented as median (interquartile 
range; number of cases is adjusted). Significant pairwise differences are 
indicated as * for Site KI and FH and † for Site FH and UM. Continuous 
variables were tested using a univariable ANOVA controlling for 
multiple comparisons using the Bonferonni post hoc test. Sex was 
tested using a χ2 test.
Abbreviations: FEV1, forced expiratory volume at 1 s; FVC, forced vital 
capacity; TLC, total lung capacity; Tx, transplantation.
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decline in FEV1 and FVC with normal TLC, in the absence of in-
fection or other causes for airflow decline,16 as well as those with 
mixed obstructive and restrictive ventilatory impairment based on 
obstruction by FEV1/FVC ratio < 0.7 or elevated RV with a con-
comitant decline in TLC. A small subset of patients with restrictive 
physiology in the presence of chronic GVHD were also included 
(N = 3 RLD only and N = 8 BOS/RLD).
2.2 | CT acquisition
CT examinations were performed using site-specific acquisition and 
reconstruction protocols (Table S1). For all sites, paired CT scans 
were acquired at full inspiration (TLC) and relaxed expiration (func-
tional residual capacity). Quantitative CT data were presented in 
Hounsfield units (HU), where stability of CT measurement for each 
scanner was monitored based on site-specific protocols. For refer-
ence, air, water, and blood attenuation values should be −1000, 0, 
and 50 HU, respectively.17
2.3 | Parametric response mappings
PRM was applied to all paired CT scans as previously described.11,14 
Briefly, lungs from both paired CT scans were segmented from the 
thoracic cavity using an in-house algorithm written in Matlab (The 
MathWorks, Inc). The whole-lung inspiratory CT scan was spatially 
aligned to the expiratory CT scan using Elastix, an open source image 
registration algorithm.18,19 This process allows the paired images to 
share the same geometric space, where each voxel, the smallest unit 
of volume in a 3-dimensional image data set, consists of HU values at 
inspiration and expiration. To mitigate the effects of noise on the PRM 
analysis, a 3 × 3 median filter was applied to all slices in the paired 
CT scans. Finally, all voxels bounded between −1000 and −250 HU 
on both paired CT scans were classified based on a scheme of 3 pre-
determined thresholds as previously described.14 Voxels with values 
greater than or equal to −950 HU and less than −810 HU at inspiration 
and greater than or equal to −856 HU at expiration were classified 
normal (PRMNorm, green voxels), greater than or equal to −950 HU and 
less than −810 HU at inspiration and less than −856 HU at expiration 
were functional small airways disease (fSAD) (PRMfSAD, yellow voxels), 
less than −950 HU at inspiration and less than −856 HU at expiration 
were emphysema (PRMEmph, red voxels), and greater than or equal to 
−810 HU at inspiration were parenchymal disease (PD) (PRMPD, purple 
voxels). The relative lung volumes, calculated as the sum of all voxels 
within a class normalized to the sum of all voxels within the expiratory 
lungs multiplied by 100, were used as global measures.
2.4 | Statistical analysis
All data values are presented as the mean ± standard deviation, un-
less specified otherwise. Site comparisons were determined for all 
variables, that is, mean and standard deviation of HU values, patient 
characteristics, and PFT and PRM measures. Analysis of variance, 
controlling for multiple comparisons using a Bonferroni post hoc 
test, and χ2 tests were used to assess site differences in continuous 
and categorical variables, respectively. Paired Student's t test was 
used to assess differences in the mean HU of ambient and tracheal 
air measured on inspiration and expiration CT scans from each site. 
PRM measures were correlated with PFT outcomes using a non-
parametric Spearman rho correlation. Finally, univariable and multi-
variable analyses were performed to determine the contributions of 
PRMfSAD and PRMPD to FEV1%, FVC%, FEV1/FVC, and TLC% using 
an ANOVA and ANCOVA controlling for site and BMI, respectively. 
Results were considered statistically significant at the 2-sided 5% 
comparison-wise significance level (P < .05). All statistical computa-
tions were performed with a statistical software package (IBM SPSS 
Statistics, v. 21). Box and whiskers plots, generated using GraphPad 
Prism 7 (San Diego, CA), are presented as the 25th and 75th percen-
tiles for the lower and upper box, respectively, median value for the 
line in the box, 5th and 95th percentiles for lower and upper whisk-
ers, respectively, and markers as outliers.
3  | RESULTS
3.1 | Subject and site characteristics
In total, 72 patients were enrolled, including 12 patients from KI, 48 
patients from FH, and 12 patients from UM (Table 1). The KI cohort 
included 6 subjects with BOS, including 3 with mixed obstruction/
restriction and 3 patients with GVHD who had restriction on PFT. 
The FH cohort were all clinically identified as BOS with airflow ob-
struction, including 5 patients with mixed obstruction/restriction. 
The UM cohort were identified as BOS and all had obstruction. 
Negligible differences were observed between patient characteris-
tics. FH patients were diagnosed up to 1.08 and 1.71 (P = .04) years 
later than patients diagnosed at KI and UM, respectively. The me-
dian FEV1% predicted at diagnosis were 49.5% (interquartile range 
[IQR] = 21.8%), 54.9% (IQR = 25.8%), and 61.0% (IQR = 22.5%) for KI, 
FH, and UM, respectively. In addition, there were no site differences 
in TLC. Significantly higher median FVC% and lower median FEV1/
FVC were observed in the FH cohort (81.5%, IQR 23.5% and 0.55, 
IQR 0.25, respectively) when compared to KI (65.5%, IQR 23.0% and 
0.72, IQR 0.29, respectively). Significant variations in the acquisi-
tion and reconstruction of chest CT scans between and within sites 
were observed. Representative CT slices acquired at full inspiration 
and expiration demonstrate the effect of imaging protocol on image 
quality and noise (Figure 1A,B). Details regarding the technical as-
pects of the CT reconstructions and analyses are provided in the 
Supplemental section. Presented in Figure 1C,D are examples of 
PRM images with corresponding scatter plots of individual lung vox-
els. All subjects had elevated levels of fSAD (the relative volume of 
lung with voxels greater than or equal to −950 HU and less than −810 
HU at inspiration and less than −856 at expiration) compared to what 
     |  2201CHENG Et al.
is observed from a healthy population (PRM-derived fSAD = 5%-
15%12-14). On close examination of Figure 1C, PRM data for the KI 
case showed less spatial consolidation (ie, noisier) of individual clas-
sifications as compared to the representative cases at FH and UM. 
Figure 2 shows the relative volume of PRM-derived Normal (Norm), 
fSAD, and PD for all subjects separated by site. Although the relative 
volumes of normal and diseased parenchyma were found to differ 
between sites, these results were not significant. FH was found to 
have higher, yet nonsignificant, values in fSAD compared to KI and 
UM. PRM-derived fSAD and PD from all 3 sites were found to be el-
evated compared to healthy smokers (8.4 ± 1% for fSAD and 11 ± 2% 
for PD) reported in our previous work.14 PRM-derived emphysema 
measurements (data not shown) were found to be significantly dif-
ferent between KI (4.0% ± 5.3%) and FH (0.9% ± 1.4%; P = .001) and 
UM (1.4% ± 1.7%; P = .04). Although the differences were significant, 
these values were small relative to PRM-derived fSAD and PD. All 
CT scans were radiographically confirmed by a trained thoracic ra-
diologist (DV) to be absent of emphysema, which suggests that site 
differences in the relative volume of emphysema are most likely at-
tributed to the higher HU scatter observed in the KI scans (Figure 1 
and Figure S1).
3.2 | Effect of disease severity and phenotype 
on PRM
Analyses were performed to identify the contribution of disease se-
verity and phenotype, as defined by PFT, on PRM measurements. 
F I G U R E  1   Effect of site-specific imaging protocol on PRM. Presented are representative axial slices from CT scans acquired at (A) 
inspiration, (B) expiration, (C) PRM overlay, and (D) corresponding PRM scatter plot from an individual case at each participating site. Peak 
voltage, tube current, slice thickness, and slice number/arrangement varied between cases. For the inspiration, CT scan protocol parameters 
were: (KI) 120 kVp, 249 mA, 0.6 mm, 708/contiguous; (FH) 120 kVp, 410 mA, 1.25 mm, 122/contiguous; and (UM) 120 kVp, 372 mA, 
1.25 mm, 521/contiguous. For the expiration, CT scan protocol parameters were: (KI) 120 kVp, 66 mA, 0.6 mm, 635/contiguous; (FH) 
120 kVp, 180 mA, 1.25 mm, 12/incremental; and (UM) 120 kVp, 376 mA, 1.25 mm, 502/contiguous. PRM-derived values over the whole 
lung are provided within an insert above each PRM image. The green value and markers represent normal parenchyma, yellow value and 
markers represent fSAD (ie, BOS), and magenta value and markers represent parenchymal disease. Age, sex, and percent predicted values of 
FEV1 and FVC for each case were: (KI) 63 y, male, 40%, and 62%; (FH) 57 y, male, 71%, and 94%; and (UM) 68 y, male, 44%, and 71%. BOS, 
bronchiolitis obliterans syndrome; CT, computed tomography; FEV1, forced expiratory volume at 1 s; FH, Fred Hutchinson Cancer Research 
Center; fSAD, functional small airways disease; FVC, forced vital capacity; KI, Karolinska University Hospital; PRM, parametric response 
mapping; UM, University of Michigan
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Figure 3 illustrates the relationship between PRM-derived fSAD and 
PD over the entire study cohort. As expected, most cases had high 
levels of fSAD (ie, obstructive phenotype). Nevertheless, there were 
18 cases, primarily from KI and FH, that were found to have PD lev-
els > 20% with relatively low levels of fSAD (<20%), which included 
6 cases of mixed (N = 3) and restrictive (N = 3) physiology by PFT.
The ability of PRM to differentiate the restrictive and obstruc-
tive phenotypes was further evaluated by comparing PRM-derived 
fSAD (obstructive component) and PD (restrictive component) to 
PFT measurements pooled over all 3 sites. As expected, a drop in 
FEV1% was found to correspond with an increase in PRM-derived 
fSAD (R = −0.236, P = .046). Likewise, for FEV1/FVC, a negative 
correlation was observed for fSAD (R = −0.689, P < .0001) (Figure 
S2), whereas a positive correlation was observed for PD (R = 0.437, 
P < .0001). These trends reversed when comparing PRM metrics 
to FVC% (fSAD: R = 0.407, P < .0001; PD: R = −0.486, P < .0001) 
and TLC (fSAD: R = 0.623, P < .0001; PD: R = −0.531, P < .0001). 
Performing the same analysis over individual site populations found 
similar correlations between PRM metrics and PFT measurements 
for KI and FH  (Table 2). UM correlations were only observed 
between fSAD and both FEV1% and FEV1/FVC; of note, all the UM 
subjects had obstruction.
To determine the contribution of PRM-derived fSAD and PD 
on these PFT metrics, a multivariable analysis was performed con-
trolling for site and BMI (Table 3). Although in a univariate analysis 
only fSAD was found to correlate with FEV1% (Table 2), both fSAD 
and PD were found to be strong parameters for FEV1%. Similar to 
the univariate analysis, PD and fSAD were strong contributors to 
statistical models of FVC% and FEV1/FVC, respectively. This is 
consistent with the negative correlation observed in the univariate 
analysis. TLC% was only found to correlate with PRM-derived fSAD.
4  | DISCUSSION
In this retrospective analysis, we found that high-resolution chest 
CT images of patients clinically diagnosed primarily with BOS from 3 
centers could be analyzed by PRM for a SAD signature. Variations in 
the acquisition of CT images across centers accounted for variation in 
the image quality. Acquisitions with reduced tube current appeared 
to affect image quality and likely accounted for background ambient 
noise (Supplemental Section). Nevertheless, variations in acquisition 
parameters did not diminish the overall ability of PRM to distinguish 
fSAD from normal and parenchymal disease. Additionally, PRM sug-
gested a signature for restrictive physiology, as the FVC % and TLC % 
negatively correlated with a parenchymal signature. RLD likely repre-
sents a manifestation of chronic GVHD in HCT recipients, analogous 
to “restrictive allograft syndrome” phenotype of chronic lung allo-
graft dysfunction described in lung transplant recipients.20 In a pro-
spective European cohort, interstitial lung disease represented 21% 
of the late-onset noninfectious lung complications after allo-HCT, 
and was associated with a prior diagnosis of chronic GVHD.7 Defining 
the mixed and restrictive PRM phenotypes of lung disease related to 
chronic GVHD will require additional work with a larger cohort.
Parametric response mapping of paired CT has been investi-
gated extensively as an analytical technique to better phenotype 
F I G U R E  2   Evaluation of the site differences in PRM 
measurements. Box and whisker plots are presented for the relative 
volume of PRM-derived measurements from paired CT scans 
acquired at each site. The line within the box, the box extremes, 
and whiskers represent the median value, 25%ile and 75%ile, and 
5%ile and 95%ile, respectively. Markers represent outliers beyond 
5%ile and 95%ile. Site differences in variables were tested using 
a univariable ANOVA controlling for multiple comparisons using 
the Bonferonni post hoc test. Significance was assessed at a P 
value of .05. No significant differences were observed between 
sites for the presented measurements. CT, computed tomography; 
FH, Fred Hutchinson Cancer Research Center; fSAD, functional 
small airways disease; PD, parenchymal disease; PRM, parametric 
response mapping; UM, University of Michigan
F I G U R E  3   Contributions of PRM-derived fSAD and PD 
in cohort. Presented is a plot of the relative volumes of fSAD 
(PRMfSAD) and PD (PRMPD) for each of the 72 subjects studied 
with color-coding for site accrual. A clear trend between the 
contribution of fSAD and PD is observed. FH, Fred Hutchinson 
Cancer Research Center; fSAD, functional small airways disease; 
KI, Karolinska University Hospital; PD, parenchymal disease; PRM, 
parametric response mapping; UM, University of Michigan
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airway obstruction in COPD.21-26 Most of these studies are associ-
ated with multicenter observational trials such as the COPDGene 
and SPIROMICS,27,28 where imaging protocols are selected to pro-
duce image quality consistent across participating sites. This allows 
consistent results in quantitative CT measures (eg, PRM) across 
participating centers. The impact of image protocol variability on 
PRM measurements has been previously evaluated, but only in the 
context of COPDGene and SPIROMICS CT acquisitions.29 Imaging 
protocols associated with large multicenter clinical trials do not nec-
essarily reflect local practices of individual hospitals. Nevertheless, 
our single-center studies have demonstrated PRM as a diagnostic 
imaging signature in BOS after HCT and lung transplant,12-14 which 
has the potential to aid in the evaluation and the definition of BOS. 
Given the potential variability of CT imaging protocols at different 
transplant centers, it was important to investigate the impact of 
technical and clinical factors on the PRM analysis.
Baseline chest CT image quality was found to vary from site to 
site and was most pronounced within the expiratory scans. Although 
acquisition and reconstruction parameters varied between sites 
(Table S1), this did not appear to affect whole-lung PRM values of 
fSAD and PD. In fact, results presented in this study suggest that 
variations in PRM-derived fSAD and PD are driven more by disease 
severity and phenotype, as shown by the differences in the PFT pa-
rameters of participants at each site. Conventional indices of airways 
obstruction, including FEV1% and FEV1/FVC, remain independently 
associated with fSAD signatures when site and BMI are taken into 
account. Correlations of these measures with pulmonary function 
measurements have shown PRM-derived fSAD and PD to identify 
obstructive and restrictive diseases. The observed correlations of 
fSAD and PD with pulmonary function parameters are consistent 
with a previously reported study evaluating PRM as a diagnostic bio-
marker of obstructive and restrictive lung disease in lung transplant 
recipients with GVHD.13 Multivariable analysis of PRM measures, 
controlling for site of accrual, found that PRM-derived fSAD and 
PD are independent measures of disease severity and phenotype 
(Table 3).
The current study has several limitations. First, this is a retrospec-
tive study and CT scans were not originally acquired for the purposes 
of PRM case-control analysis. Due to the wide variability in scanner 
type, acquisition, and reconstruction, there was an insufficient num-
ber of cases to fully evaluate each of the many parameters that affect 
PRM measurements. This also made it infeasible to acquire controls, 
PRM Class PFT KI (N = 12) FH (N = 48) UM (N = 12)
PRMfSAD FEV1 (% predicted) −0.309, 0.329 −0.208, 0.156 −0.718, 0.002
FVC (% predicted) 0.634, 0.027 0.438, 0.002 −0.473, 0.121
FEV1/FVC −0.778, 0.003 −0.682, <0.0001 −0.705, 0.023 
(N = 10)




PRMPD FEV1 (% predicted) 0.530, 0.076 −0.127, 0.391 −0.387, 0.214
FVC (% predicted) −0.725, 0.008 −0.516, <0.0001 −0.194, 0.546
FEV1/FVC 0.953, <0.0001 0.301, 0.038 0.255, 0.476 
(N = 10)




Note: Data for each cell represent the R value and its P value. Those parameters found to be 
significant are bolded.
Abbreviations: FEV1, forced expiratory volume at 1 s; fSAD, functional small airways disease; FVC, 
forced vital capacity; PFT, pulmonary function test; PD, parenchymal disease; PRM, parametric 
response mapping; TLC, total lung capacity. Statistical significance was assessed at a P value < .05.
TA B L E  2   Correlations of PRM and PFT 
for each site
TA B L E  3   Multivariable regression
 PRMfSAD PRMPD BMI Site (FH) Site (KI)
FEV1 (% predicted) −0.449, 0.001 −0.477, 0.001 0.585, 0.062   
FVC (% predicted)  −0.552, <0.0001 0.711, 0.028 11.544, 0.027  
FEV1/FVC −0.005, <0.0001    0.104, 0.028
TLC (% predicted) 0.404, 0.001   −11.570, 0.057 −13.737, 0.050
Data for each cell represent the parameter coefficient and its P value. Those parameters found to be significant are bolded. Statistical significance 
was assessed at a P value < .05. The site University of Michigan (UM) serves as the reference, thus the coefficients for the other sites (FH, KI) 
represent the intercept relative to UM. For example, FVC% in the FH population is 11.544 higher than in the UM population. For FEV1/FVC, KI is 
0.105 higher than UM.
Abbreviations: BMI, body mass index in units of kg/cm2; FEV1, forced expiratory volume at 1 s; FH, Fred Hutchinson Cancer Research Center; fSAD, 
functional small airways disease; FVC, forced vital capacity; KI, Karolinska University Hospital; PD, parenchymal disease; TLC, total lung capacity.
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that is, HCT recipients without GVHD scanned using a similar CT pro-
tocol, from the 3 centers that participated in this study. The cohort 
analysis was skewed to FH, which had significantly more patients 
than the other sites. It is possible that the difference in demographics 
was responsible for the variations in the PRM signatures. The num-
ber of cases was limited for an exploration of restrictive phenotypes. 
Nonetheless, the purpose of the study was to establish PRM as a 
valid technique for the diagnosis of clinically recognized BOS, and 
the study reflects real-world conditions in which heterogeneous phe-
notypes of BOS exist16 and different centers will serve populations 
reflective of that region. The correlation between PRM and PFT mea-
sures and PRM-derived fSAD and PD, regardless of site, suggests that 
PRM will still be diagnostically useful in multiple settings.
For PRM to be broadly applicable and diagnostically accurate, 
particularly for the diagnosis of early-stage disease, it may be help-
ful to clarify the protocol requirements for a high-resolution CT 
imaging and to standardize the acquisition of high-resolution CT 
images. Based on the results reported in this study, sufficiently high 
X-ray tube currents, even if incremental scans are required to re-
duce X-ray exposure, are recommended for minimizing image noise, 
which would improve PRM measurements. Although recent studies 
evaluating the utility of PRM as an early detector of BOS are prom-
ising, prospective studies in which HRCT are used for screening of 
patients at risk for pulmonary GVHD disease will help validate the 
use of PRM for early detection of disease onset and progression.
ACKNOWLEDG MENTS
This work was supported by the US National Institutes of Health 
research grants R44HL118837, R44HL140894, R01HL139690, 
R35CA197701, P30CA015704, and P30CA046592.
DISCLOSURE
The authors of this manuscript have conflicts of interest to disclose 
as described by the American Journal of Transplantation. CJG has a 
financial interest in Imbio, LLC, which has licensed the PRM technol-
ogy. CH is an employee and stock option holder at Imbio, LLC. The 
other authors have no conflicts of interest to disclose.
DATA AVAIL ABALIT Y S TATEMENT
The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
ORCID
Craig J. Galban  https://orcid.org/0000-0001-5596-7487 
R E FE R E N C E S
 1. Williams KMCJ, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans 
after allogeneic hematopoietic stem cell transplantation. JAMA. 
2009;302(3):306-314.
 2. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epi-
demiology after allogeneic hematopoietic cell transplantation. Biol 
Blood Marrow Transplant. 2011;17(7):1072-1078.
 3. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis 
obliterans syndrome after allogeneic hematopoietic stem cell 
transplantation-an increasingly recognized manifestation of chronic 
graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 
Suppl):S106-S114.
 4. Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and 
treatment of pulmonary chronic GVHD: report from the consen-
sus conference on clinical practice in chronic GVHD. Bone Marrow 
Transplant. 2011. Epub 2011/03/29. doi: bmt201135 [pii].
 5. Williams KM. How I treat bronchiolitis obliterans syndrome after he-
matopoietic stem cell transplantation. Blood. 2017;129(4):448-455.
 6. Yanik G, Kitko C. Management of noninfectious lung injury fol-
lowing hematopoietic cell transplantation. Curr Opin Oncol. 
2013;25(2):187-194.
 7. Bergeron A, Chevret S, Peffault de Latour R, et al. Noninfectious 
lung complications after allogeneic haematopoietic stem cell trans-
plantation. Eur Respir J. 2018;51(5):1702617.
 8. Bergeron A, Cheng GS. Bronchiolitis obliterans syndrome and other 
late pulmonary complications after allogeneic hematopoietic stem 
cell transplantation. Clin Chest Med. 2017;38(4):607-621.
 9. Cheng GS, Storer B, Chien JW, et al. Lung function trajectory in 
bronchiolitis obliterans syndrome after allogeneic hematopoietic 
cell transplant. Ann Am Thorac Soc. 2016;13(11):1932-1939.
 10. Jagasia MH, Greinix HT, Arora M, et al. Diagnosis and staging working 
group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.
 11. Galban CJ, Han MK, Boes JL, et al. Computed tomography-based 
biomarker provides unique signature for diagnosis of COPD pheno-
types and disease progression. Nat Med. 2012;18(11):1711-1715.
 12. Verleden SE, Vos R, Vandermeulen E, et al. Parametric response 
mapping of bronchiolitis obliterans syndrome progression after 
lung transplantation. Am J Transplant. 2016;16(11):3262-3269.
 13. Belloli EA, Degtiar I, Wang X, et al. Parametric response mapping as 
an imaging biomarker in lung transplant recipients. Am J Respiratory 
Critical Care Med. 2017;195(7):942-952.
 14. Galban CJ, Boes JL, Bule M, et al. Parametric response mapping 
as an indicator of bronchiolitis obliterans syndrome after hema-
topoietic stem cell transplantation. Biol Blood Marrow Transplant. 
2014;20(10):1592-1598.
 15. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of 
Health Consensus Development Project on Criteria for Clinical 
Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis 
and Staging Working Group Report. Biol Blood Marrow Transplant. 
2015;21(3):389-401.e1.
 16. Bergeron A, Godet C, Chevret S, et al. Bronchiolitis obliterans syn-
drome after allogeneic hematopoietic SCT: phenotypes and prog-
nosis. Bone Marrow Transplant. 2013;48(6):819-824.
 17. Stoel BC, Stolk J. Optimization and standardization of lung densi-
tometry in the assessment of pulmonary emphysema. Invest Radiol. 
2004;39(11):681-688.
 18. Shamonin DP, Bron EE, Lelieveldt BP, Smits M, Klein S, Staring M. 
Alzheimer's Disease Neuroimaging I. Fast parallel image registration 
on CPU and GPU for diagnostic classification of Alzheimer's dis-
ease. Frontiers in Neuroinformatics. 2013;7. https://doi.org/10.3389/
fninf.2013.00050.
 19. Klein S, Staring M, Murphy K, Viergever MA, Pluim J. elastix: a tool-
box for intensity-based medical image registration. IEEE Trans Med 
Imaging. 2010;29(1):196-205.
 20. Shah RJ, Diamond JM. Update in chronic lung allograft dysfunction. 
Clinics Chest Med. 2017;38(4):677-692
 21. Vasilescu DM, Martinez FJ, Marchetti N, et al. Non-invasive imag-
ing biomarker identifies small airway damage in severe COPD. Am 
J Respir Crit Care Med. 2019. https://doi.org/10.1164/rccm.20181 
1-2083OC.
 22. Martinez CH, Diaz AA, Meldrum C, et al. Age and small airway 
imaging abnormalities in subjects with and without airflow ob-
struction in SPIROMICS. Am J Respiratory Critical Care Med. 
2017;195(4):464-472.
     |  2205CHENG Et al.
 23. Labaki WW, Gu T, Murray S, et al. Voxel-wise longitudinal paramet-
ric response mapping analysis of chest computed tomography in 
smokers. Academic Radiol. 2019;26(2):217-223.
 24. Han MK, Tayob N, Murray S, et al. Association between emphy-
sema and chronic obstructive pulmonary disease outcomes in the 
COPDGene and SPIROMICS cohorts: a post hoc analysis of two 
clinical trials. Am J Respir Crit Care Med. 2018;198(2):265-267.
 25. Boes JL, Hoff BA, Bule M, et al. Parametric response mapping mon-
itors temporal changes on lung CT scans in the subpopulations and 
intermediate outcome measures in COPD Study (SPIROMICS). Acad 
Radiol. 2015;22(2):186-194.
 26. Bhatt SP, Soler X, Wang X, et al. Association between functional 
small airway disease and FEV1 decline in chronic obstructive pul-
monary disease. Am J Respir Crit Care Med. 2016;194(2):178-184.
 27. Regan EA, Hokanson JE, Murphy JR, et al. Genetic Epidemiology 
of COPD (COPDGene) study design. J Chron Obstruct Pulmon Dis. 
2011;7(1):32-43
 28. Sieren JP, Newell JD, Barr R, et al. SPIROMICS protocol for multi-
center quantitative computed tomography to phenotype the lungs. 
Am J Respir Crit Care Med. 2016;194(7):794-806
 29. Boes JL, Bule M, Hoff BA, et al. The impact of sources of variabil-
ity on parametric response mapping of lung CT scans. Tomography. 
2015;1(1):69-77.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Cheng G-S, Selwa KE, Hatt C, et al. 
Multicenter evaluation of parametric response mapping as an 
indicator of bronchiolitis obliterans syndrome after 
hematopoietic stem cell transplantation. Am J Transplant. 
2020;20:2198–2205. https://doi.org/10.1111/ajt.15814
